6-K 1 d10192006k.htm

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF THE

SECURITIES EXCHANGE ACT OF 1934

 

For the month of October 2020

Commission File Number 001-37652

 

Midatech Pharma PLC

(Translation of registrant’s name into English)

 

Oddfellows House,

19 Newport Road,

Cardiff, CF24 0AA, United Kingdom

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F  x                Form 40-F  o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  o

 

This Report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the Company’s Registration Statements on Form F-3 (File No. 333-233901) and Form F-1 (File No. 333-240984).

 

 

 

  
 

 

SUBMITTED HEREWITH

 

Attached to the Registrant’s Form 6-K filing for the month of October 2020, and incorporated by reference herein, is:

 

Exhibit No.

  Description
   
99.1  

Press release, dated October 19, 2020 entitled

 

“Headline Results of MTX110 Phase I DIPG Study,

Phase II Dose Confirmed and Encouraging Survival Data”

 

  
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Midatech Pharma PLC
     
     
Date: October 19, 2020 By:

/s/ Stephen Stamp

 

   

Stephen Stamp

Chief Executive Officer, Chief Financial Officer

 

  
 

 

Exhibit Index

 

     

Exhibit No.

  Description
   
99.1  

Press release, dated October 19, 2020 entitled

 

“Headline Results of MTX110 Phase I DIPG Study,

Phase II Dose Confirmed and Encouraging Survival Data”